Benefits of hospitalist care confirmed in new study

December 19, 2007

In the largest study to date evaluating the outcome of in-hospital care by various physician types, findings show that care by hospitalists resulted in shorter stays and lower costs to patients.

Study results are reported in the Dec. 20, 2007 issue of the "New England Journal of Medicine."

Findings show that compared to general internists, patients cared for by hospitalists had a length of stay shortened by 12 percent, or nearly half a day, and modestly lower costs. The two groups exhibited similar mortality and hospital readmission rates. When compared to family physicians, patients overseen by hospitalists also stayed in the hospital almost half a day less. Treatment cost, mortality and readmission rates were similar.

Researchers from the University of California, San Francisco and Tufts University led the study team.

The study is based on data from 45 hospitals across the country that participate in Perspective, a national database used for hospital quality and utilization benchmarking. Researchers gathered information including patient mortality, readmission, length-of-stay and cost of treatment. Using these criteria, they compared the outcome of 76, 926 patients under the care of hospitalists, general internists and family physicians across seven common inpatient conditions: heart failure, pneumonia, stroke, chronic obstructive coronary disease, chest pain, heart attack and urinary tract infection.

Hospitalist medicine is one of the fastest growing specialties in medicine, the researchers said, yet little evidence existed to support the benefit of hospitalist care before this study.

"Even though the differences in the length of stay may seem small, when multiplied by the thousands of admissions that hospitalists see each year, the effects can be quite large," said Peter Lindenauer, MD, MSc, lead author of the study and associate professor of medicine at Baystate Medical Center and the Tufts University School of Medicine.

"A .4 day shorter length-of-stay per case multiplied by 5,000 cases annually will save 2,000 bed days and enable 500 more patients to be cared for each year without increasing the number of hospital beds. Moreover, there aren't many interventions capable of achieving these kinds of efficiency gains," he added.

Researchers noted that the benefit to hospitals of more efficient patient traffic can be used to justify the cost of training programs.

"It appears clear that the benefits of hospitalist care really exist, so we can now turn our attention to moving the field of hospital medicine forward. Research into hospitalists is just one manifestation of research into better ways to structure programs," said Andrew Auerbach, MD, MPH, senior author on the study and associate professor of medicine at UCSF. "The important thing from here is that hospital medicine capitalizes on opportunities to further innovate hospital services to maximize effectiveness, safety, and efficiency of healthcare."

In an accompanying editorial in NEJM, Laurence F. McMahon, Jr., MD, MPH, from the Department of Internal Medicine and Health Management and Policy at the University of Michigan, identifies hospitalists as an integral part of hospital care and the study as definitive evidence of the benefit they provide. He suggests that hospitalists as well as academic and policy leaders turn their focus to addressing the looming shortage of hospitalists and other generalists by addressing payment reform, and by increasing the role of hospitalists in academic medical centers, through the establishment of strong fellowship programs in hospital medicine.

"Instead of comparison studies, new investigations should focus on quality improvement, comparative effectiveness, clinical informatics, the safety of patients and the translation of new medical advances to clinical practice," McMahon said.
-end-
The study was supported by a patient safety research and training grant from the Agency for Healthcare Research and Quality and by a Doris Duke Clinical Scientist Development Award.

Co-authors on the study include Michael B. Rothberg, MD, MPH, and Evan M. Benjamin, MD, both of Baystate Medical Center and the Tufts University School of Medicine; Penelope S. Pekow, PhD, Baystate Medical Center and the University of Massachusetts-Amherst School of Public Health and Health Sciences; and Christopher Kenwood, University of Massachusetts-Amherst School of Public Health and Health Sciences.

UCSF is a leading university dedicated to defining health worldwide through advanced biomedical research, graduate level education in the life sciences and health professions, and excellence in patient care.

University of California - San Francisco

Related Mortality Articles from Brightsurf:

Being in treatment with statins reduces COVID-19 mortality by 22% to 25%
A research by the Universitat Rovira i Virgili (URV) and Pere Virgili Institut (IISPV) led by LluĂ­s Masana has found that people who are being treated with statins have a 22% to 25% lower risk of dying from COVID-19.

Mortality rate higher for US rural residents
A recent study by Syracuse University sociology professor Shannon Monnat shows that mortality rates are higher for U.S. working-age residents who live in rural areas instead of metro areas, and the gap is getting wider.

COVID-19, excess all-cause mortality in US, 18 comparison countries
COVID-19 deaths and excess all-cause mortality in the U.S. are compared with 18 countries with diverse COVID-19 responses in this study.

New analysis shows hydroxychloroquine does not lower mortality in COVID-19 patients, and is associated with increased mortality when combined with the antibiotic azithromycin
A new meta-analysis of published studies into the drug hydroxychloroquine shows that it does not lower mortality in COVID-19 patients, and using it combined with the antibiotic azithromycin is associated with a 27% increased mortality.

Hydroxychloroquine reduces in-hospital COVID-19 mortality
An Italian observational study contributes to the ongoing debate regarding the use of hydroxychloroquine in the current pandemic.

What's the best way to estimate and track COVID-19 mortality?
When used correctly, the symptomatic case fatality ratio (sCFR) and the infection fatality ratio (IFR) are better measures by which to monitor COVID-19 epidemics than the commonly reported case fatality ratio (CFR), according to a new study published this week in PLOS Medicine by Anthony Hauser of the University of Bern, Switzerland, and colleagues.

COVID-19: Bacteriophage could decrease mortality
Bacteriophage can reduce bacterial growth in the lungs, limiting fluid build-up.

COPD and smoking associated with higher COVID-19 mortality
Current smokers and people with chronic obstructive pulmonary disease (COPD) have an increased risk of severe complications and higher mortality with COVID-19 infection, according to a new study published May 11, 2020 in the open-access journal PLOS ONE by Jaber Alqahtani of University College London, UK, and colleagues.

Highest mortality risks for poor and unemployed
Large dataset shows that income, work status and education have a clear influence on mortality in Germany.

Addressing causes of mortality in Zambia
Despite the fact that people in sub-Saharan Africa are now living longer than they did two decades ago, their average life expectancy remains below that of the rest of the world population.

Read More: Mortality News and Mortality Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.